Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Shares of Pfizer (NYSE:PFE) have delivered negative returns since I started covering the stock and the last four months have not been great either as it is down another 12% since my previous ...

After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., is returning to her previous employer: Big Pharma Pfizer. After ...

OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director ...

Conservative commentator Megyn Kelly claimed the Pfizer COVID vaccine left her with an auto-immune disorder in explosive new comments on her latest podcast episode Wednesday. Kelly, 54 ...

Feb 24 (Reuters) - Pfizer (PFE.N), opens new tab on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing ...

Pfizer's disclosure Friday that it is ending global development and commercialization efforts for its hemophilia B treatment Beqvez brings an inauspicious ending to a gene therapy that got its ...

WASHINGTON--Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a ...